retatrutide safety trials ⚠️ “RETA” is NOT an approved weight-loss medication. Social media is full of “RETA” offers—but here's what you should know. is a promising investigational medicine developed by Eli Lilly. The Phase Important Safety Notice Retatrutide is

Read our learning article for practical advice on safe and effective switching between weight loss medication: Switching between weight-loss medications Stopping GLP-1s There is some evidence to suggest that rapid weight loss is much more effective than gradual weight loss in achieving and sustaining a clinically meaningful drop in weight

The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide

For Continuing Therapy If you are already on Zepbound: A renewal PA is required at 29 weeks After that, PAs are required every 12 months You must generally demonstrate a 5% reduction in weight from your baseline Important Clarification for Members Switching from Another GLP-1 If you are continuing therapy on a GLP-1 weight loss medication other than Zepbound, such as Wegovy: even if your BMI is now below 30, if you have lost 5% or more of your baseline weight, you may still meet prior authorization criteria for Zepbound under continuation-of-therapy guidelines

This move makes it easier and more cost-effective for people to get this popular weight-loss drug

Muscle weakness, low energy levels, and fatigue are symptoms of carnitine deficiency